Recent 8-K filings for BHVN
Highest-materiality recent filing
Biohaven reports positive clinical data for opakalim in epilepsy and BHV-1300/BHV-1400 in autoimmune diseases at R&D Day
- Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
- 54% of focal epilepsy patients on opakalim achieved ≥50% seizure reduction over six months in open-label extension.
-
Opakalim 75 mg prolonged median time to second seizure to 141 days vs 47 days for placebo in idiopathic generalized epilepsy trial.
-
Biohaven establishes $350M at-the-market equity offering via amended agreement with J.P. Morgan
Amendment No. 2 to Equity Distribution Agreement allows up to $350M in common share sales.
-
Biohaven shareholders elect three directors, ratify EY, approve say-on-pay at 2026 meeting
Michael T. Heffernan elected with 76.1M for, 15.1M against, 2.0M abstain; 32.1M broker non-votes.
-
Biohaven Q1 net loss $130.5M; pivotal epilepsy & obesity data due 2H 2026
Net loss $130.5M ($0.88/sh) vs $221.7M ($2.17/sh) in Q1 2025; non-GAAP adjusted loss $102.2M ($0.69/sh).
-
Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M
Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).
-
Biohaven files investor presentation; content unavailable in filing excerpt
Investor presentation furnished as Exhibit 99.1 on January 12, 2026.
-
Biohaven to issue 12.5M shares at $10 each to Janus Henderson, raising $125M gross
12,500,000 common shares at $10.00 per share, $125M gross proceeds expected.
-
Biohaven closes $200M public offering of 26.8M shares at $7.50/share
Gross proceeds of approximately $200M from 26,833,334 common shares, including full exercise of underwriters' 3.5M share option.
-
Biohaven reports Q3 net loss $173.4M, plans 60% R&D spend cut to focus on three late-stage programs
Net loss $173.4M ($1.64/share) vs $160.3M ($1.70/share) YoY; non-GAAP loss $155.9M ($1.47/share).
-
FDA cancels advisory committee meeting for Biohaven's troriluzole NDA; decision still Q4 2025
FDA informed Biohaven on Aug 21, 2025 that an advisory committee meeting is no longer needed for troriluzole NDA review.
-
Biohaven amends Knopp deal: royalty cut to mid-single digits, milestones reduced by >$800M
Removed up to $562.5M in commercial sales milestones; reduced developmental/regulatory milestones from $575M to up to $210M.
-
Biohaven reports Q2 net loss $198M, cash $408.2M; OCD trial fails, VYGLXIA PDUFA in Q4 2025
Net loss of $198.1M ($1.94 per share) vs $319.8M in Q2 2024; no revenue, clinical-stage biopharma.
-
Biohaven files 8-K with investor presentation; content not disclosed
Filed June 4, 2025 under Item 7.01 with investor presentation as Exhibit 99.1.
-
FDA extends Biohaven's troriluzole PDUFA date to 4Q 2025, plans advisory committee meeting
FDA extends PDUFA date by 3 months to 4Q 2025 for troriluzole NDA for spinocerebellar ataxia (SCA).
-
Biohaven Q1 net loss $221.7M; announces $600M Oberland capital deal for troriluzole launch
Net loss of $221.7M ($2.17 per share); non-GAAP adjusted net loss $166.8M ($1.64 per share).
-
Vlad Coric, M.D. re-elected with 61,631,560 votes for, 16,931,405 against; Kishan Mehta re-elected with 62,967,729 for, 15,578,703 against.
-
First tranche $250M funded at closing on or before April 30, 2025.
-
Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA
Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).
-
Biohaven furnishes investor presentation for January 2025; full content not available.
Presentation attached as Exhibit 99.1, but the exhibit text is truncated or missing.
-
Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024
Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).
-
Biohaven completes $287.5M equity offering; 6.05M shares at $47.50
Sold 6,052,631 common shares including full underwriter option at $47.50/share.
-
Biohaven troriluzole pivotal SCA study meets primary endpoint; NDA planned Q4 2024
Troriluzole 200 mg once-daily met primary endpoint on f-SARA change from baseline at 3 years in all SCA genotypes.
-
Biohaven expands at-the-market equity facility by $300M to total potential issuance
Amendment No. 1 increases existing ATM capacity by $300M in common shares; sales via J.P. Morgan as manager.
-
Biohaven files prospectus for resale of 1.87M shares by selling shareholder
Prospectus supplement filed for resale of 1,872,874 common shares issued to a selling shareholder as share consideration.
-
Biohaven Q2 net loss $3.64/sh; pipeline highlights MoDE degrader data and FDA alignment for BHV-8000
Net loss of $319.8M ($3.64/sh) in Q2 2024 vs $1.32/sh in Q2 2023; cash ~$440M.
-
Biohaven files prospectus supplement for resale of 211,418 common shares by selling shareholders
Prospectus supplement filed on May 17, 2024 for resale of 211,418 common shares issued as share consideration.
-
Net loss $179.5M ($2.20/shr); non-GAAP adjusted net loss $144.6M ($1.77/shr); both more than doubled vs Q1 2023.
-
Julia P. Gregory elected with 60,724,030 votes for, 412,143 against, 135,964 abstained.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.70 · Most common event other_material